Seroprevalence of pertussis in Madagascar and implications for vaccination.
Madagascar
pertussis
serology
vaccination
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
16 11 2020
16 11 2020
Historique:
pubmed:
17
11
2020
medline:
26
1
2021
entrez:
16
11
2020
Statut:
epublish
Résumé
Pertussis is a highly contagious infectious disease and remains an important cause of mortality and morbidity worldwide. Over the last decade, vaccination has greatly reduced the burden of pertussis. Yet, uncertainty in individual vaccination coverage and ineffective case surveillance systems make it difficult to estimate burden and the related quantity of population-level susceptibility, which determines population risk. These issues are more pronounced in low-income settings where coverage is often overestimated, and case numbers are under-reported. Serological data provide a direct characterisation of the landscape of susceptibility to infection; and can be combined with vaccination coverage and basic theory to estimate rates of exposure to natural infection. Here, we analysed cross-sectional data on seropositivity against pertussis to identify spatial and age patterns of susceptibility in children in Madagascar. A large proportion of individuals surveyed were seronegative; however, there were patterns suggestive of natural infection in all the regions analysed. Improvements in vaccination coverage are needed to help prevent additional burden of pertussis in the country.
Identifiants
pubmed: 33190665
doi: 10.1017/S0950268820002800
pii: S0950268820002800
pmc: PMC7770380
doi:
Substances chimiques
Pertussis Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e283Subventions
Organisme : NLM NIH HHS
ID : DP2 LM013102
Pays : United States
Organisme : Wellcome Trust
ID : 106866/Z/15/Z
Pays : United Kingdom
Références
Epidemiol Infect. 2018 Oct;146(14):1807-1810
pubmed: 29986784
Nat Commun. 2019 Apr 9;10(1):1633
pubmed: 30967543
Expert Rev Vaccines. 2014 Sep;13(9):1081-106
pubmed: 25093268
J Infect. 2014 Jan;68 Suppl 1:S119-24
pubmed: 24103807
Bull World Health Organ. 2009 Jul;87(7):535-41
pubmed: 19649368
Pediatr Infect Dis J. 2015 Apr;34(4):333-8
pubmed: 25764094
Syst Rev. 2015 May 01;4:62
pubmed: 25930111
APMIS. 2009 Nov;117(11):797-807
pubmed: 19845530
Int Health. 2015 Nov;7(6):426-32
pubmed: 25788580
Epidemiol Infect. 2019 Jan;147:e199
pubmed: 31364527
Front Immunol. 2019 Jul 03;10:1344
pubmed: 31333640
Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
PLoS One. 2012;7(10):e48684
pubmed: 23119090
Vaccine. 2016 Jul 29;34(35):4103-4109
pubmed: 27349841
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671):
pubmed: 25964453
Lancet Infect Dis. 2003 Jul;3(7):413-8
pubmed: 12837346
Pathog Dis. 2015 Oct;73(7):
pubmed: 26208655
J Med Microbiol. 2016 Jul;65(7):649-657
pubmed: 27075481
Lancet Infect Dis. 2017 Sep;17(9):889-890
pubmed: 28623145
Scand J Infect Dis. 2014 Apr;46(4):280-7
pubmed: 24520981
Heliyon. 2018 Mar 07;4(3):e00563
pubmed: 29560473
J Clin Microbiol. 2000 Feb;38(2):800-6
pubmed: 10655388
Epidemiol Infect. 2005 Feb;133(1):159-71
pubmed: 15724723
Vaccine. 2016 Mar 14;34(12):1423-5
pubmed: 26562318
J Infect Dis. 2002 Aug 1;186(3):415-8
pubmed: 12134239